A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Phase of Trial: Phase II/III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs 18F DCFPyL (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms OSPREY
- Sponsors Progenics Pharmaceuticals
- 16 Nov 2017 Planned number of patients changed from 290 to 377.
- 16 Nov 2017 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
- 16 Nov 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.